3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER_GOV
1
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Colorectal Neoplasms
240
Rectal Neoplasms
93
Colonic Neoplasms
91
Pancreatic Neoplasms
87
Stomach Neoplasms
68
Neoplasm Metastasis
47
Esophageal Neoplasms
41
Neoplasms
36
Small Cell Lung Carcinoma
29
Lung Neoplasms
29
Neuroblastoma
28
Glioblastoma
28
Glioma
27
Brain Neoplasms
26
Carcinoma, Non-Small-Cell Lung
22
Adenocarcinoma Of Esophagus
20
Gliosarcoma
19
Breast Neoplasms
18
Astrocytoma
18
Esophageal Squamous Cell Carcinoma
17
Central Nervous System Neoplasms
17
Unspecified Adult Solid Tumor, Protocol Specific
16
Oligodendroglioma
13
Adenocarcinoma
13
Rhabdomyosarcoma
10
Gastrointestinal Neoplasms
10
Biliary Tract Neoplasms
10
Sarcoma
9
Gallbladder Neoplasms
9
Cholangiocarcinoma
9
Interventions
Fulvestrant
5
dalpiciclib
3
Letrozole
3
ribociclib
2
palbociclib
2
fluzoparib
2
exemestane
2
apatinib
2
Anastrozole
2
trastuzumab deruxtecan
1
sacituzumab govitecan
1
pyrotinib
1
pegfilgrastim
1
patritumab deruxtecan
1
olaparib
1
irinotecan sucrosofate
1
abemaciclib
1
Zoledronic Acid
1
Rogaratinib
1
Patient Reported Outcome Measures
1
Paclitaxel
1
Neoadjuvant Therapy
1
Liposomes
1
Irinotecan
1
Ga(III)-DOTATOC
1
Everolimus
1
Cell Separation
1
Capecitabine
1
Bevacizumab
1
Aromatase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Breast Cancer Metastatic
×
Irinotecan
×
Clear all
NCT03328884
2025-04-23
Phenomenal
MedSIR
Phase 2
Completed
55 enrolled